Startup Funding News
Explore funding rounds, the companies behind them and the investors taking part.
- Rounds
- 752 All time
- Disclosed funding
- $25.4B 616 disclosed amounts
- Median round
- $15.8M Of disclosed amounts
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
| N NavidenceCompany profile Provides AI-native platform with standardized computable definitions of diseases and outcomes for real-world evidence research Provides AI-native platform with standardized computable definitions of diseases and outcomes for real-world evidence research | Undisclosed | StrategicUndisclosed | Healthtech | United States | Investors | |
| V VillageCompany profile Builds AI-powered platform connecting families, providers, and payers for coordinated specialty pediatric care Builds AI-powered platform connecting families, providers, and payers for coordinated specialty pediatric care | $9.5M | Seed | Healthtech | United States | Investors | |
| LB Latus Bio, Inc.Company profile Engineers scalable AAV gene therapies for CNS and rare diseases including Huntington's disease and CLN2 Engineers scalable AAV gene therapies for CNS and rare diseases including Huntington's disease and CLN2 | $97M | Series A | Healthtech, Biotech | United States | Investors | |
| EH Enzo HealthCompany profile AI-driven platform automating home health workflows from referral to reimbursement for post-acute care providers AI-driven platform automating home health workflows from referral to reimbursement for post-acute care providers | $20M | Series A | Healthtech | United States | Investors | |
| E EnteroBiotixCompany profile Develops full-spectrum microbiome therapeutics for gastrointestinal diseases including IBS Develops full-spectrum microbiome therapeutics for gastrointestinal diseases including IBS | £19M | Series B | Healthtech, Biotech | United Kingdom | Investors | |
| GP General ProximityCompany profile Develops induced proximity medicines targeting undruggable proteins across oncology and cardiometabolic disease Develops induced proximity medicines targeting undruggable proteins across oncology and cardiometabolic disease | $20M | StrategicUndisclosed | Healthtech, Biotech | United States | Investors | |
| OB Oberland BiotechCompany profile Develops and trades nutritional supplements and food products internationally Develops and trades nutritional supplements and food products internationally | CHF 2.5M | Seed | Healthtech, Biotech | Switzerland | Investors | |
| M Decodes cellular networks to advance human health | $20M | Undisclosed | Healthtech, Biotech | Sweden | Investors | |
| T Provides AI-powered digital diagnostics for anatomic and clinical pathology | $15M | Undisclosed | Healthtech | United States | Investors | |
| IS Develops projection-based clinical guidance platform for doctors | $8.4M | Seed | Healthtech | United States | Investors |
Active investors in this selection
All investors →Ranked by rounds participated in · All time
- 1General Catalyst
Baba, Disha (formerly Curelink), Thatch
23rounds2led - 2Y Combinator (YC)
Vitalize, Angle Health, Metriport
21rounds0led - 3Alumni Ventures
MintNeuro, Evvy, Hopscotch Primary Care
13rounds0led - 4Andreessen Horowitz (a16z)
Sharp Performance, General Medicine, Devoted Health
12rounds2led - 5Khosla Ventures
Even Healthcare, Abby Care, Rightway
11rounds1led
Latest digests
Archive →Explore published rounds while the next edition is being prepared.
Browse rounds by topic
Geography
Featured selections
Nordic Foodtech Fund II pairs early capital with scientific expertise
An EIF pledge of up to €30m supports a fund targeting €80m for science-led agrifood companies.
Read the research →